TNF and obesity disorder: Therefore, it can be thought that the distribution volume of a nonlipophilic drug such as IFX may be reduced due to the presence of excess adipose tissue, and this may partially explain its limited effect in patients with obesity compared to the effect of other subcutaneously administered anti-TNF agents (etanercept and adalimumab).